Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
San Antonio, TX
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
Murray, UT
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
Murray, UT
Click here to add this to my saved trials
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
Woodstock, VT
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
Woodstock, VT
Click here to add this to my saved trials
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
Richmond, VA
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
Seattle, WA
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Status: Enrolling
Updated:  10/26/2015
Research Site
mi
from
Penticton,
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Status: Enrolling
Updated: 10/26/2015
Research Site
mi
from
Penticton,
Click here to add this to my saved trials
Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium
Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium: A Four-arm Prospective, Randomized, Double-blind, Placebo-controlled Pilot Study
Status: Enrolling
Updated:  10/26/2015
Rochester General Hospital
mi
from
Rochester, NY
Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium
Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium: A Four-arm Prospective, Randomized, Double-blind, Placebo-controlled Pilot Study
Status: Enrolling
Updated: 10/26/2015
Rochester General Hospital
mi
from
Rochester, NY
Click here to add this to my saved trials
Reducing Unsafe Alcohol Use in HIV-Positive Individuals
Reducing Unsafe Drinking in HIV Primary Care
Status: Enrolling
Updated:  10/28/2015
New York State Psychiatric Institute/ St. Vincent's Hospital
mi
from
New York, NY
Reducing Unsafe Alcohol Use in HIV-Positive Individuals
Reducing Unsafe Drinking in HIV Primary Care
Status: Enrolling
Updated: 10/28/2015
New York State Psychiatric Institute/ St. Vincent's Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Safety & Health Improvement: Enhancing Law Enforcement Departments
Safety & Health Improvement: Enhancing Law Enforcement Departments
Status: Enrolling
Updated:  10/28/2015
Oregon Health and Science University
mi
from
Portland, OR
Safety & Health Improvement: Enhancing Law Enforcement Departments
Safety & Health Improvement: Enhancing Law Enforcement Departments
Status: Enrolling
Updated: 10/28/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
Status: Enrolling
Updated:  10/28/2015
Clinical Research Facility
mi
from
Garden Grove, CA
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
Status: Enrolling
Updated: 10/28/2015
Clinical Research Facility
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
Status: Enrolling
Updated:  10/28/2015
Clinical Research Facility
mi
from
Kissimmee, FL
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
Status: Enrolling
Updated: 10/28/2015
Clinical Research Facility
mi
from
Kissimmee, FL
Click here to add this to my saved trials
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
Status: Enrolling
Updated:  10/28/2015
Clinical Research Facility
mi
from
Atlanta, GA
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
Status: Enrolling
Updated: 10/28/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
Status: Enrolling
Updated:  10/28/2015
Clinical Research Facility
mi
from
Hoffman Estates, IL
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
Status: Enrolling
Updated: 10/28/2015
Clinical Research Facility
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
Status: Enrolling
Updated:  10/28/2015
Clinical Research Facility
mi
from
Cedarhurst, NY
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
Status: Enrolling
Updated: 10/28/2015
Clinical Research Facility
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
Status: Enrolling
Updated:  10/28/2015
Clinical Research Facility
mi
from
Austin, TX
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
Status: Enrolling
Updated: 10/28/2015
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
Status: Enrolling
Updated:  10/28/2015
mi
from
Banfield,
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
Status: Enrolling
Updated: 10/28/2015
mi
from
Banfield,
Click here to add this to my saved trials
Health Protection & Promotion for Oregon Correctional Officers
Health Protection & Promotion for Oregon Correctional Officers
Status: Enrolling
Updated:  10/28/2015
Oregon Health and Science University
mi
from
Portland, OR
Health Protection & Promotion for Oregon Correctional Officers
Health Protection & Promotion for Oregon Correctional Officers
Status: Enrolling
Updated: 10/28/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy
A Randomized Megestrol Acetate/Placebo Controlled Trial in Pediatric Patients With Malignancies With Weight Loss/Anorexia
Status: Enrolling
Updated:  10/29/2015
The Mayo Clinic
mi
from
Rochester, MN
Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy
A Randomized Megestrol Acetate/Placebo Controlled Trial in Pediatric Patients With Malignancies With Weight Loss/Anorexia
Status: Enrolling
Updated: 10/29/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists
Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists
Status: Enrolling
Updated:  10/29/2015
The Scripps Research Institute
mi
from
La Jolla, CA
Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists
Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists
Status: Enrolling
Updated: 10/29/2015
The Scripps Research Institute
mi
from
La Jolla, CA
Click here to add this to my saved trials
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Status: Enrolling
Updated:  10/30/2015
University of California at Los Angeles
mi
from
Los Angeles, CA
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Status: Enrolling
Updated: 10/30/2015
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Status: Enrolling
Updated:  10/30/2015
Yale University
mi
from
New Haven, CT
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Status: Enrolling
Updated: 10/30/2015
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Status: Enrolling
Updated:  10/30/2015
Massachusetts General Hospital
mi
from
Lexington, MA
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Status: Enrolling
Updated: 10/30/2015
Massachusetts General Hospital
mi
from
Lexington, MA
Click here to add this to my saved trials
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Status: Enrolling
Updated:  10/30/2015
Seattle Children's Hospital
mi
from
Seattle, WA
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Status: Enrolling
Updated: 10/30/2015
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Status: Enrolling
Updated:  10/30/2015
Emory University
mi
from
Atlanta, GA
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Status: Enrolling
Updated: 10/30/2015
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Partnering With Autistic Adults to Improve Healthcare
Partnering With Autistic Adults to Develop Tools to Improve Primary Healthcare
Status: Enrolling
Updated:  10/30/2015
Oregon Health and Science University
mi
from
Portland, OR
Partnering With Autistic Adults to Improve Healthcare
Partnering With Autistic Adults to Develop Tools to Improve Primary Healthcare
Status: Enrolling
Updated: 10/30/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Clinical Study Centers, LLC
mi
from
Little Rock, AR
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Clinical Study Centers, LLC
mi
from
Little Rock, AR
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Pacific Research Partners, LLC
mi
from
Oakland, CA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Pacific Research Partners, LLC
mi
from
Oakland, CA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Research Across America
mi
from
Santa Ana, CA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Research Across America
mi
from
Santa Ana, CA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Gulfcoast Clinical Research
mi
from
Fort Myers, FL
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Gulfcoast Clinical Research
mi
from
Fort Myers, FL
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Uptown Research Institute, Llc
mi
from
Chicago, IL
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Uptown Research Institute, Llc
mi
from
Chicago, IL
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Alexian Brothers Behavioral Health Hospital
mi
from
Hoffman Estates, IL
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Alexian Brothers Behavioral Health Hospital
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
AMR Baber Research Inc.
mi
from
Naperville, IL
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
AMR Baber Research Inc.
mi
from
Naperville, IL
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Goldpoint Clinical Research
mi
from
Indianapolis, IN
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Cypress Medical Research Center, LLC
mi
from
Wichita, KA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Cypress Medical Research Center, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
McLean Hospital
mi
from
Belmont, MA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
McLean Hospital
mi
from
Belmont, MA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
St Charles Psychiatric Associates - Midwest Research Group
mi
from
St. Charles, MO
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
St Charles Psychiatric Associates - Midwest Research Group
mi
from
St. Charles, MO
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Pacific Research for Research and Evaluation
mi
from
Albuquerque, NM
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Pacific Research for Research and Evaluation
mi
from
Albuquerque, NM
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Wake Research Associates, LLC
mi
from
Raleigh, NC
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Wake Research Associates, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Community Research
mi
from
Cincinnati, OH
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Community Research
mi
from
Cincinnati, OH
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
IPS Research Company
mi
from
Oklahoma City, OK
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
IPS Research Company
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
The Clinical Trials Center, LLC
mi
from
Jenkintown, PA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
The Clinical Trials Center, LLC
mi
from
Jenkintown, PA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Suburban Research Associates
mi
from
Media, PA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Suburban Research Associates
mi
from
Media, PA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Clinical Trials Research Services, LLC
mi
from
Pittsburgh, PA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Clinical Trials Research Services, LLC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Clinical NeuroScience Solutions, Inc.
mi
from
Memphis, TN
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Clinical NeuroScience Solutions, Inc.
mi
from
Memphis, TN
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Future Search Trials
mi
from
Austin, TX
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Future Search Trials
mi
from
Austin, TX
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
FutureSearch Trials of Dallas, LP
mi
from
Dallas, TX
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
FutureSearch Trials of Dallas, LP
mi
from
Dallas, TX
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Grayline Clinical Drug Trials
mi
from
Wichita Falls, TX
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Grayline Clinical Drug Trials
mi
from
Wichita Falls, TX
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Radiant Research, Inc.
mi
from
Murray, UT
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Radiant Research, Inc.
mi
from
Murray, UT
Click here to add this to my saved trials